miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment
Breast cancer, which is the most common malignancy in women, does not form a uniform nosological unit but represents a group of malignant diseases with specific clinical, histopathological, and molecular characteristics. The increasing knowledge of the complex pathophysiological web of processes con...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/20/7691 |
| _version_ | 1797550651599749120 |
|---|---|
| author | Erik Kudela Marek Samec Lenka Koklesova Alena Liskova Peter Kubatka Erik Kozubik Tomas Rokos Terezia Pribulova Eva Gabonova Marek Smolar Kamil Biringer |
| author_facet | Erik Kudela Marek Samec Lenka Koklesova Alena Liskova Peter Kubatka Erik Kozubik Tomas Rokos Terezia Pribulova Eva Gabonova Marek Smolar Kamil Biringer |
| author_sort | Erik Kudela |
| collection | DOAJ |
| description | Breast cancer, which is the most common malignancy in women, does not form a uniform nosological unit but represents a group of malignant diseases with specific clinical, histopathological, and molecular characteristics. The increasing knowledge of the complex pathophysiological web of processes connected with breast cancercarcinogenesis allows the development of predictive and prognostic gene expressionand molecular classification systems with improved risk assessment, which could be used for individualized treatment. In our review article, we present the up-to-date knowledge about the role of miRNAs and their prognostic and predictive value in luminal A breast cancer. Indeed, an altered expression profile of miRNAs can distinguish not only between cancer and healthy samples, but they can classify specific molecular subtypes of breast cancer including HER2, Luminal A, Luminal B, and TNBC. Early identification and classification of breast cancer subtypes using miRNA expression profilescharacterize a promising approach in the field of personalized medicine. A detection of sensitive and specific biomarkers to distinguish between healthy and early breast cancer patients can be achieved by an evaluation of the different expression of several miRNAs. Consequently, miRNAs represent a potential as good diagnostic, prognostic, predictive, and therapeutic biomarkers for patients with luminal A in the early stage of BC. |
| first_indexed | 2024-03-10T15:32:23Z |
| format | Article |
| id | doaj.art-50aa04f649274c15881ed2bf6297e0fb |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T15:32:23Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-50aa04f649274c15881ed2bf6297e0fb2023-11-20T17:29:58ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-012120769110.3390/ijms21207691miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal TreatmentErik Kudela0Marek Samec1Lenka Koklesova2Alena Liskova3Peter Kubatka4Erik Kozubik5Tomas Rokos6Terezia Pribulova7Eva Gabonova8Marek Smolar9Kamil Biringer10Department of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaDepartment of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaClinic of Surgery and Transplant Center, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, SlovakiaClinic of Surgery and Transplant Center, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, SlovakiaDepartment of Obstetrics and Gynecology, Martin University Hospital and Jessenius Faculty of Medicine in Martin, Comenius University of Bratislava, 03601 Martin, SlovakiaBreast cancer, which is the most common malignancy in women, does not form a uniform nosological unit but represents a group of malignant diseases with specific clinical, histopathological, and molecular characteristics. The increasing knowledge of the complex pathophysiological web of processes connected with breast cancercarcinogenesis allows the development of predictive and prognostic gene expressionand molecular classification systems with improved risk assessment, which could be used for individualized treatment. In our review article, we present the up-to-date knowledge about the role of miRNAs and their prognostic and predictive value in luminal A breast cancer. Indeed, an altered expression profile of miRNAs can distinguish not only between cancer and healthy samples, but they can classify specific molecular subtypes of breast cancer including HER2, Luminal A, Luminal B, and TNBC. Early identification and classification of breast cancer subtypes using miRNA expression profilescharacterize a promising approach in the field of personalized medicine. A detection of sensitive and specific biomarkers to distinguish between healthy and early breast cancer patients can be achieved by an evaluation of the different expression of several miRNAs. Consequently, miRNAs represent a potential as good diagnostic, prognostic, predictive, and therapeutic biomarkers for patients with luminal A in the early stage of BC.https://www.mdpi.com/1422-0067/21/20/7691breast cancerluminal Aestrogen receptormiRNAtamoxifenprognosis |
| spellingShingle | Erik Kudela Marek Samec Lenka Koklesova Alena Liskova Peter Kubatka Erik Kozubik Tomas Rokos Terezia Pribulova Eva Gabonova Marek Smolar Kamil Biringer miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment International Journal of Molecular Sciences breast cancer luminal A estrogen receptor miRNA tamoxifen prognosis |
| title | miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment |
| title_full | miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment |
| title_fullStr | miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment |
| title_full_unstemmed | miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment |
| title_short | miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment |
| title_sort | mirna expression profiles in luminal a breast cancer implications in biology prognosis and prediction of response to hormonal treatment |
| topic | breast cancer luminal A estrogen receptor miRNA tamoxifen prognosis |
| url | https://www.mdpi.com/1422-0067/21/20/7691 |
| work_keys_str_mv | AT erikkudela mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT mareksamec mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT lenkakoklesova mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT alenaliskova mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT peterkubatka mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT erikkozubik mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT tomasrokos mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT tereziapribulova mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT evagabonova mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT mareksmolar mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment AT kamilbiringer mirnaexpressionprofilesinluminalabreastcancerimplicationsinbiologyprognosisandpredictionofresponsetohormonaltreatment |